Rosiglitazone . maleate

Specifications / Handling

More Information
Product Details
Synonyms	BRL 49653C; Rosiglitazone XR; Avandia
Product Type	Chemical
Properties
Formula	C₁₈H₁₉N₃O₃S . C₄H₄O₄
MW	357.4 . 116.1
Merck Index	14: 8265
CAS	155141-29-0
Purity Chemicals	≥98% (NMR)
Appearance	White to off-white powder.
Solubility	Soluble in ethanol or buffered aqueous solutions with pH 2.3.
Identity	Determined by IR and ¹H-NMR.
InChi Key	SUFUKZSWUHZXAV-BTJKTKAUSA-N
Smiles	OC(=O)\C=C/C([O-])=O.C[NH+](CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	+4°C
Use/Stability	Stable for at least 2 years after receipt when stored at +4°C. Stock solutions are stable for at least 3 months when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Same activities as rosaglitazone (Prod. No. AG-CR1-3570) but different formulation.
Antidiabetic, hypoglycemic agent [1, 5].
Potent and selective peroxisome proliferator-activated receptor γ (PPAR-γ) agonist [2, 3].
Potent insulin sensitizing agent binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. Ameliorates insulin resistance [4-6, 8].
Improves blood pressure and vascular function [7].
Enhances proliferation of endogenous neural progenitor cells (NPCs) [9].
Anti-inflammatory compound [10, 11].
Has controversial therapeutic effects on the cardiovascular system [12].
Promotes adipocyte differentiation of mesenchymal stem cells (MSCs) [13].

Product References

[[ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents: B.C. Cantello, et al.; J. Med. Chem. 37, 3977 (1994)
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ): J.M. Lehmann, et al.; J. Biol. Chem. 270, 12953 (1995)
Rosiglitazone: J.A. Balfour & G.L. Plosker; Drugs 57, 921 (1999) (Review)
Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes: G.A. Knock, et al.; Eur. J. Pharmacol. 368, 103 (1999)
Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes: A. Cheng-Lai & A. Levine; Heart Dis. 2, 326 (2000) (Review)
Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review: J.M. Malinowski & S. Bolesta; Clin. Ther. 22, 1151 (2000) (Review)
PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice: M.J. Ryan, et al.; Hypertension 3, 661 (2004)
Rosiglitazone: a review of its use in type 2 diabetes mellitus: E.D. Deeks & S.J. Keam; Drugs 67, 2747 (2007) (Review)
Rosiglitazone enhances the proliferation of neural progenitor cells and inhibits inflammation response after spinal cord injury: Q.Q. Meng, et al.; Neurosci. Lett. 503, 191 (2011)
Inhibitory effects of rosiglitazone on lipopolysaccharide-induced inflammation in a murine model and HK-2 cells: W.M. Wang, et al.; Am. J. Nephrol. 34, 152 (2011)
PPARγ agonist rosiglitazone ameliorates LPS-induced inflammation in vascular smooth muscle cells via the TLR4/TRIF/IRF3/IP-10 signaling pathway: Y. Ji, et al.; Cytokine 55, 409 (2011)
PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system? S. Palee, et al.; World J. Cardiol. 3, 144 (2011)
Rosiglitazone-induced adipogenesis in a bone marrow mesenchymal stem cell line: D. Wang, et al.; Biomed. Sci. Instrum. 47, 213 (2011)
Rosiglitazone requires hepatocyte PPARγ expression to promote steatosis in male mice with diet-induced obesity: S.M. Lee, et al.; Endocrinology, 175, (2021)

Call	+41 61 926 6040
Fax	+41 61 926 6049